Targeted drug shows promise for rare HER2-Positive cancers

This study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want to see if it can shrink tumors or stop them from growing. About 38 adults with advanced or hard-to-treat cancers are taking part.